|Bid||22.39 x 4000|
|Ask||22.40 x 1200|
|Day's Range||21.94 - 22.99|
|52 Week Range||12.56 - 25.05|
|Beta (3Y Monthly)||1.43|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 7, 2019 - May 13, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.00|
How These Biotechnology Stocks Are Positioned in March(Continued from Prior Part)Analysts’ recommendations and target price Wall Street analysts expect an upside potential of 18.37% for Array Biopharma (ARRY) based on the company’s closing price
BOULDER, Colo. , March 18, 2019 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced that the National Comprehensive Cancer Network ® (NCCN ® ) has updated their Clinical Practice Guidelines ...
Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like Array BioPharma Inc. (NASDAQ:ARRY), with a market cap of US$4.8b, are often out of theRead More...
BOULDER, Colo. , March 5, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the 39 th Annual Cowen Health Care Conference ...
NEW YORK, March 04, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
Insider transactions can provide a valuable glimpse into how corporate insiders really view a company. As the famous saying goes: Actions speak louder than words. And the advantage here is that insiders such as executives and directors may well have a greater insight into the company and its outlook than the average investor.That's why tracking insider transactions - whether it's insider buying or insider selling - can be a valuable strategy. Especially when there are multiple insiders either selling or buying stocks around the same time.Today, we're looking at the TipRanks Daily Insider Transactions tool to highlight some of the stocks that have insiders heading for the door. This could be because they believe shares are trading at an attractive price and want to take profits - potentially before prices fall.Crucially, the insider tool we used here allows you to focus on only informative transactions - and therefore excludes uninformative transactions that do not necessarily indicate insider sentiment. For instance, some insiders simply exercise stock options ahead of expiry dates, which doesn't tell us much.With that in mind, here are five stocks seeing notable insider selling right now. SEE ALSO: 19 Best Stocks to Buy for 2019 (And 5 to Sell)
BOULDER, Colo. , Feb. 21, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the SVB Leerink Partners 8 th Annual Global ...
Array Biopharma Inc NASDAQ NMS:ARRYView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for ARRY with between 5 and 10% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on January 10. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ARRY totaled $3.24 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 5) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) Array ...
rose 11% on strong revenue growth and after its loss for its fiscal second quarter was narrower than expectations. The company -- with several drugs in its development pipeline -- posted a loss for the period ended Dec. 31, of 5 cents a share. The loss was narrower than the Zacks Consensus Estimate of 16 cents and its loss the same quarter the previous year of 17 cents.
A Boulder-based biotech company that has recently transitioned to a fully-integrated firm with drugs on the market and a pipeline of new cancer-fighting products on the way reported a strong second quarter mostly due to sales of its new drug combo that combats melanoma. "This was another strong quarter for us," said CEO Ron Squarer. The revenue growth is attributed to the sale of its skin cancer-fighting drug combination Braftovi and Mektovi.
Array BioPharma (ARRY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Array BioPharma (ARRY) delivered earnings and revenue surprises of 68.75% and 68.41%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
The Boulder, Colorado-based company said it had a loss of 5 cents per share. The results beat Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was ...
- Strong quarter for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in U.S. with $22.7 million in net product sales, which represents quarter over quarter growth of 62% - - Combination of BRAFTOVI, MEKTOVI ...